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Abstract
Background: There remains uncertainty in whether vitamin D status affects cancer survival. We investigated
whether vitamin D (± calcium) supplementation affects cancer survival in women.
Methods: Participants were women aged ≥55 years identified from the UK Clinical Practice Research Datalink
(CPRD) with a first diagnosis of breast, colorectal, lung, ovarian or uterine cancer between 2002 and 2009, and at
least 5 years of CPRD data prior to diagnosis. Cox proportional hazards were used to estimate hazard ratios (HR)
and 95 % confidence intervals (CI) of the relationship between pre-diagnostic vitamin D supplementation and
all-cause mortality. To avoid confounding by indication, the primary analysis compared women with 3+ to 1–2
(but no more) vitamin D prescriptions. Models were adjusted for pre-diagnostic body mass index, smoking,
alcohol and deprivation. A sensitivity analysis excluded supplements prescribed in the year prior to diagnosis.
Results: Exposure to 3 or more versus 1 to 2 prescriptions of vitamin D was not associated with survival from
any of the cancers studied. Any vitamin D prescription, compared to never having been prescribed one, was
associated with a better survival from breast cancer (HR 0.78, 95 % CI 0.70 to 0.88). The sensitivity analysis suggested a
possible detrimental effect of vitamin D supplementation on lung cancer outcomes (HR for 3 versus 1 or 2
prescriptions 1.22 (95 % CI 0.94 to 1.57); HR for any versus no prescriptions 1.09 (0.98 to 1.22)).
Conclusions: We found no evidence that vitamin D supplementation is associated with survival among women
with cancer. Previous observational findings of beneficial effects of vitamin D supplementation on cancer survival
may be confounded.
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Background
The benefits of vitamin D have received much attention,
deriving primarily from observational data, which sug-
gest that low vitamin D status is associated with higher
mortality [1, 2]. Key to understanding this association is
to determine whether low vitamin D levels cause prema-
ture death, or whether the vitamin D levels are a conse-
quence of poor health. If vitamin D is simply a marker
of health status, supplementation is unlikely to have a
direct benefit on mortality. If the association is causal,
then vitamin D supplementation is likely to be of some
benefit in reducing mortality. An individual patient data
meta-analysis of randomised controlled trials (RCTs)
found lower all-cause mortality in patients receiving
vitamin D and calcium compared to placebo [3], and a
meta-analysis of three studies also demonstrated this in
relation to cancer mortality in patients with cancer [4].
Observational evidence relating vitamin D levels to
cancer survival is strongest for colorectal cancer, in
which ecological and individual level data consistently
show better survival in people with higher vitamin D
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levels [5]. However, a review concluded that there is no
strong nor consistent evidence that vitamin D reduces
the risk of ovarian cancer mortality [6].
There is very limited evidence on this topic from
RCTs. Follow-up of the Women’s Health Initiative trial
found a suggestion of a beneficial effect of vitamin D
supplementation on cancer mortality (hazard ratio (HR)
0.89, 95 % confidence interval (CI): 0.77 to 1.03) [7].
Follow-up of participants in the RECORD trial found no
effect of vitamin D supplementation on cancer mortality
in an intention to treat analysis, and a possible beneficial
effect in an analysis adjusted for compliance [8]. When
the two trials were pooled, there was a suggestion of a
beneficial effect of vitamin D on colorectal cancer mor-
tality (risk ratio 0.78; 95 % CI: 0.52 to 1.17) [5].
Vitamin D and calcium supplements are routinely
given to older women to prevent osteoporotic fractures.
Current vitamin D supplementation guidelines recom-
mend daily supplements containing 10 mcg amongst
people aged 65 years or over, or who are not exposed to
much sun (for example, those who cover up their skin
for cultural reasons, who are housebound on confined
indoors for long periods, or those who have darker skin)
[9]. Approximately 5 % of women over the age of 60 in
the UK have received at least one year’s worth of supple-
ments [10]. Whether these supplements affect survival
following a cancer diagnosis, remains unclear.
In the absence of randomised evidence, alternatives
are required to address issues of causality. Observational
studies of vitamin D supplementation are prone to con-
founding by indication, whereby an apparent association
between vitamin D and an outcome is due to character-
istics of those prescribed vitamin D (including the indi-
cation for prescription), not vitamin D itself [11]. The
association of vitamin D and survival may be con-
founded if women given a prescription might be mani-
festing symptoms that are indicative of cancer and are
predictive of prognosis or survival, but have been mis-
taken for (e.g. bone pain) or cause (e.g. anorexia affect-
ing nutrient intake or frailty impeding ability to go
outdoors) vitamin D deficiency. The presence of osteo-
porosis, which is related to low estrogen levels, may also
influence vitamin D supplement use and breast cancer
prognosis. The association may also be confounded if
manifesting symptoms cause discontinuation of vitamin
D supplementation. To address this, we conducted an
analysis with an a priori comparison of women who
discontinue compared to those who continue with
prescribed vitamin D supplements. We have previously
reported no strong link between continuing vs. discon-
tinuation vitamin D supplementation and the risk of
breast, colorectal, lung, ovarian or uterine cancer among
women with cancer in the UK Clinical Practice Research
Datalink (CPRD, formerly the General Practice Research
Database (GPRD)) [12]. Here we report on the effect of
prediagnostic prescribed vitamin D supplements on all
cause mortality in a cohort of women with cancer.
Methods
We conducted an analysis of cancer survival within the
CPRD, a database of anonymised, longitudinal medical
records of patients registered with contributing primary
care practices across the UK (CPRD, personal communi-
cation). As of September 2014, the CPRD database
covers approximately 8.8 % of the UK population from
684 GP practices (CPRD, personal communication).
There are research standard quality data for 13.58 M
patients in CPRD, of which 5.69 M are active (still alive
and registered with the GP practice). Data is said to be
of research standard quality if the record satisfies pre-
specified minimum data quality criteria that include
thresholds for practice death recording and missing
data [13, 14]. Access to CPRD data was granted by the
CPRD-Independent Scientific Advisory Committee
(CPRD-ISAC), an advisory body established to provide
advice on request to access data provided by the CPRD
[15]. Use of anonymised CPRD data is approved by the
Trent Multi-Centre Research Ethics Committee (05/
MRE/04/87).
Participants were women aged 55 years or over at the
time of a first diagnosis of breast, colorectal, lung, ovar-
ian or uterine cancer between 2002 and 2011, repre-
senting post-menopausal women. This analysis was
limited to women as the focus of the grant application
was common cancers in women. Codes used to identify
participants were listed by the authors, and supple-
mented by those suggested by CPRD staff. These are
available on request from the authors. Further inclusion
criteria were: the practice having at least 5 years’ worth
of research standard quality data prior to the date of
cancer diagnosis. Follow-up extended from the date of
cancer diagnosis to the earliest of: death, leaving the
practice, or the final date of data collection, defined on
a practice level. Information on the cause of death was
not available in our dataset and we only present sur-
vival from all causes.
A total of 21,932 women were diagnosed with one of
the five cancers of interest during the study period. Two
women who were recorded as dying, one and 3 months
respectively, prior to their cancer diagnosis were ex-
cluded. A further 365 women who died on their date of
diagnosis were also excluded, leaving 21,565 women for
analysis (11,112 women with breast cancer; 4122 with
colorectal cancer; 3352 with lung cancer and 2979 with
gynaecological cancer).
Women were classified as either having received none,
1–2 (reference) or 3 or more prescriptions for vitamin
D ± calcium (BNF Chapters 9.6.4 and 9.5.1.1) in the
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5 years prior to cancer diagnosis. Associations of vitamin
D supplementation with survival from each cancer were
determined using Cox proportional hazards models. Ro-
bust standard errors were used to account for clustering
at a practice level. Adherence to the proportional haz-
ards assumption was tested graphically and empirically,
using Schoenfeld residuals. Basic models were adjusted
for the following covariates: age (as a continuous vari-
able, and in six 5-year age bands, from 55 to 59 to the
upper age band being 80 years and over), period of
diagnosis (calendar years 2002–2003, 2004–2005,
2006–2007, 2008–2009, 2010–2011). Multivariable
models also included smoking (never, current and ex),
alcohol consumption (any vs none/ex status), body
mass index (underweight: <18.5, normal: 18.5–24.9,
overweight: 25–29.9 and obese: ≥30 kg/m2) and
deprivation, measured using the Index of Multiple
Deprivation (IMD) score. The IMD is a small area level
measure of socio-economic status (based on patients’
area of residence at the time of diagnosis), which is
computed from a number of social and economic indi-
cators (housing, employment, income, access to ser-
vices, education and skills, crime, living environment)
[16]. Approximately half the CPRD practices consented to
their patients’ addresses being linked to an IMD score.
Study-specific quintiles of this score were used in the ana-
lysis. Missing data for all potential confounders were
retained in the analysis, coded to a separate category.
There were no consistent prescribing patterns by season
in the years included in the study period (data not shown)
and this was not adjusted for in the analysis.
To assess the effect of altered prescribing of vitamin D
supplements around the time of a cancer diagnosis, a sen-
sitivity analysis was undertaken, excluding women who re-
ceived their first prescription of vitamin D (± calcium)
within a year prior to diagnosis.
We have also conducted a sensitivity analysis only in-
cluding women aged 60 and over. This strategy was
used to exploit the free prescription coverage for these
women, who may be less likely to be consuming
vitamin D from over the counter sources. In this age
older group, therefore, misclassification of vitamin D
supplementation may be less likely to distort the results.
We found no difference between this analysis and our
results including the entire sample (data not shown).
Results
Of the 21,932 women included in the analysis, 18,998
(88 %) did not have any vitamin D prescription during
the period from their GP practice becoming up to re-
search standard and the date of their cancer diagnosis.
Nine percent (n = 1906) had three or more prescriptions
and 3 % (n = 661) had one or two prescriptions only.
The median duration of intake was 56 days (interquartile
range, IQR, 30–100) for patients with 1–2 prescriptions
and 504 days (IQR 240–1050) for patients with 3 or
more prescriptions. There was a strong relationship be-
tween period of diagnosis and vitamin D prescription,
with the proportion of women having had three or more
prescriptions rising from 4 % in 2002–03 to 13 % in
2010–11.
Table 1 shows the baseline characteristics of the study
cohort. We identified 11,112 breast, 4122 colorectal,
3352 lung and 2979 gynaecological (ovarian and uter-
ine) cancer cases. The vast majority (97 %) of those
taking supplements were prescribed vitamin D in com-
bination with calcium rather than alone. The median
length of follow-up was 30.4 months (inter quartile
range 1 to 115 months). During this follow-up time,
there were 7736 deaths (2103 in women with breast
cancer; 1726 in women with colorectal cancer; 2756 in
women with lung cancer and 1151 in women with a gy-
naecological cancer).
Exposure to three or more prescriptions of vitamin D
was not associated with survival from any of the cancers
that we studied, compared with 1–2 prescriptions
(Table 2). This effect remained the same after adjust-
ment for BMI, smoking status, alcohol drinking and
level of deprivation. For breast, colorectal and gynaeco-
logical cancers, having been prescribed a vitamin D sup-
plement was associated with lower mortality than not
having been prescribed a supplement, although this only
reached conventional levels of statistical significance in
women with breast cancer.
In the sensitivity analysis (Table 3), excluding all sup-
plements prescribed in the 1 year prior to diagnosis did
not materially alter the interpretation of the results, al-
though there was a suggestion in these analyses that
vitamin D supplementation may be associated with a
higher risk of mortality in women with lung cancer.
Discussion
This study, designed to address the issue confounding
by indication [11] and reverse causality, found that
pre-diagnostic vitamin D supplementation has little
effect on survival in women with one of four major
cancers. Furthermore, our results highlight the need for
caution in interpreting observational data of vitamin D
supplementation and cancer survival, given the marked
protective effect on mortality seen in women with breast
cancer who are prescribed supplements, compared with
those never prescribed supplements.
A high validity of using cancer diagnoses as recorded
in the GPRD has previously been reported [17]. Even if
some cases of cancers were omitted erroneously from
the dataset, it is unlikely that this would introduce any
selection bias into the study, since the association
between vitamin D supplementation and mortality is
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Table 1 Characteristics of women with specific cancers, identified through the General Practice Research Datalink (2002–2011)
Breast Colorectal Lung Gynaecologicala
N = 11,112 N = 4122 N = 3352 N = 2979
n % n % n % n %
Supplementation
None 9952 89.6 3566 86.5 2793 83.3 2687 90.2
1–2 prescriptions 318 2.9 130 3.2 141 4.2 72 2.4
3+ prescriptions 842 7.6 426 10.3 418 12.5 220 7.4
Age group
<60 2019 18.2 324 7.9 249 7.4 484 16.3
60–64 2213 19.9 441 10.7 438 13.1 586 19.7
65–69 1888 17.0 564 13.7 516 15.4 557 18.7
70–74 1427 12.8 648 15.7 628 18.7 514 17.3
75–79 1339 12.1 761 18.5 651 19.4 360 12.1
80 and above 2226 20.0 1384 33.6 870 26.0 478 16.1
Period of diagnosis
2002–03 1809 16.3 587 14.2 453 13.5 438 14.7
2004–05 2582 23.2 920 22.3 736 22.0 670 22.5
2006–07 3182 28.6 1175 28.5 981 29.3 841 28.2
2008–09 3289 29.6 1308 31.7 1067 31.8 951 31.9
2010–11 250 2.3 132 3.2 115 3.4 79 2.7
Vital status at follow-up
Alive 9009 81.1 2396 58.1 596 17.8 1828 61.4
Dead 2103 18.9 1726 41.9 2756 82.2 1151 38.6
Smoking
Never 6793 61.1 2539 61.6 523 15.6 1936 65.0
Current 1426 12.8 444 10.8 1399 41.7 308 10.3
Ex 2559 23.0 1020 24.8 1383 41.3 654 22.0
Missing 334 3.0 119 2.9 47 1.4 81 2.7
Alcohol
None/ex 2569 23.1 1081 26.2 984 29.4 716 24.0
Any 7383 66.4 2533 61.5 1980 59.1 1930 64.8
Missing 1160 10.4 508 12.3 388 11.6 333 11.2
BMIb
Underweight 155 1.4 118 2.9 221 6.6 41 1.4
Normal 3576 32.2 1451 35.2 1314 39.2 788 26.5
Overweight 3498 31.5 1227 29.8 883 26.3 877 29.4
Obese 2656 23.9 804 19.5 539 16.1 951 31.9
Missing 1227 11.0 522 12.7 395 11.8 322 10.8
Deprivation levelc
Quintile 1 (deprived) 913 8.2 391 9.5 508 15.2 270 9.1
Quintile 2 1064 9.6 411 10.0 362 10.8 268 9.0
Quintile 3 1152 10.4 383 9.3 255 7.6 305 10.2
Quintile 4 1181 10.6 403 9.8 204 6.1 319 10.7
Quintile 5 (affluent) 1217 11.0 369 9.0 204 6.1 313 10.5
Missing 5585 50.3 2165 52.5 1819 54.3 1504 50.5
aGynaecological cancers included 1372 women with ovarian cancer, 1599 women with uterine cancer and 8 women with other unspecificed gynaecological cancers
bUnderweight: <18.5 kg/m2; normal weight: 18.5 to <25 kg/m2; overweight 25 to <30 kg/m2; obese > =30 kg/m2
cStudy-specific quintiles of the Index of Multiple Deprivation (IMD) score, based on patient’s address
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unlikely to differ between those included and those
excluded. In the validation study, the median time
between diagnosis in GPRD and in the cancer registry
data was 11 days [17], suggesting that our sensitivity
analysis of excluding a full year prior to the date of
diagnosis would be sufficiently sensitive.
A systematic review of the validity of reporting in
GPRD found just one validation study, on sudden
death, which was well reported [18]. Potential under-
ascertainment of outcome may have diluted our effect,
but is unlikely to have been an important source of bias
in this study.
We were limited by our measure of supplementation;
in particular, we had no information on vitamin D
bought over the counter. Some women who had not re-
ceived any vitamin D prescription may have bought
vitamin D. However, it is unlikely that women who had
received a prescription would instead buy vitamin D,
since prescriptions for women are free after age 60 years.
Therefore, this should have had minimal impact on our
a priori results. In CPRD, dosage is reported, but
instructions for use are not complete, precluding a cal-
culation of average daily dose, or equivalent. We have
previously reported a moderate degree of correlation
between number of prescriptions and duration of intake
(r2 = 0.66, p < 0.01) [12]. Any exposure misclassification
is likely to be non-differential, and therefore have diluted
our results towards the null effect, rather than to have
caused measurement bias.
We also do not have any information on adherence
to vitamin D supplementation in the UK. Previous
studies have shown that among elderly female hip
fracture patients, compliance to recommended supple-
ments was low (28.9 %), but that it can be increased
through written recommendations in the hospital
discharge letter [19]. In the UK, current guidelines
include recommendations to improve vitamin D access
for women over the age of 65, including free prescrip-
tions to women over 60. These guidelines may keep
non-adherece to a lower level.
We were unable to adjust for key clinical determinants
of survival, such as stage of disease. There is some evi-
dence that low levels of vitamin D may be associated
with faster progression of cancer [20]. For example, in
the Health, Eating, Activity, and Lifestyle study, stage of
disease predicted vitamin D levels, independent of other
potential confounders [21].
Other studies have demonstrated that vitamin D levels
may be related to adverse prognostic indicators, such as
tumour size (but not grade) [22] and hormone receptor
Table 2 The association of vitamin D and calcium supplementation with survival from selected cancers in women
Deaths Cases Person- Basic model Adjusted model
Years HR 95 % CI HR 95 % CI
Breast cancer
3+ prescriptions 228 842 2408.5 1.01 0.79 to 1.29 1.02 0.79 to 1.32
1–2 prescriptions 86 318 974.9 1 1
Any 314 1160 3383.3 0.80 0.71 to 0.90 0.78 0.70 to 0.88
None 1789 9952 38168.7 1 1
Colorectal cancer
3+ prescriptions 191 426 929.7 0.82 0.61 to 1.10 0.81 0.59 to 1.11
1–2 prescriptions 61 130 282.1 1 1
Any 252 556 1203.8 0.91 0.79 to 1.04 0.90 0.78 to 1.04
None 1474 3566 10090.6 1 1
Lung cancer
3+ prescriptions 323 418 384.0 0.91 0.73 to 1.12 0.86 0.70 to 1.07
1–2 prescriptions 120 141 134.1 1 1
Any 443 559 518.1 1.05 0.96 to 1.16 1.06 0.96 to 1.17
None 2313 2793 2954.1 1 1
Gynaecologic cancer
3+ prescriptions 98 220 538.1 0.74 0.49 to 1.10 0.84 0.59 to 1.30
1–2 prescriptions 36 72 152.7 1 1
Any 134 292 690.9 0.87 0.72 to 1.05 0.89 0.73 to 1.07
None 1017 2687 8033.1 1 1
The basic model is adjusted for age and period; the adjusted model is further adjusted for smoking, alcohol, BMI and area-level deprivation
Jeffreys et al. BMC Cancer  (2015) 15:670 Page 5 of 7
profiles with poorer prognosis (but not tumour size or
invasiveness) [23]. Although we could not test this, it
seems plausible that the lack of adjustment of key
prognostic markers will not have affected our infer-
ences of an effect of vitamin D on survival to a strong
degree. Given that our exposure and reference groups
differed by discontinuation rather than by initiation of
supplementation, it seems unlikely that the two groups
would differ by key determinants of survival. Indeed,
this has been empirically shown in a study of ovarian
cancer [24].
It is worth noting that most studies looking at cancer
progression used blood levels of vitamin D as its meas-
ure, and might not be directly comparable to our study
using vitamin D prescriptions. Vitamin D supplementa-
tion might not correlate with serum levels of vitamin D,
since sun exposure and intake of vitamin D food sources
affects vitamin D serum levels. Nevertheless, vitamin D
from sun exposure is limited in the UK, as much of the
country is situated above the latitude that permits opti-
mal vitamin D synthesis, particularly during fall and
winter. The elderly, such as the women in our study
population, also spend relatively large amounts of time
indoors, have reduced dermal capacity to synthesize
vitamin D and were more likely to use sun protection
when outdoors.
More comparable clinical trials have shown inconsist-
ent results and it remains unclear whether the post-
diagnostic supplementation of patients with cancer can
improve survival. Three trials (summarised in [25]) of
vitamin D supplementation in men with prostate cancer
provided conflicting results; after the promsing ASCENT
trial, the ASCENT-II trial was stopped early, due to a
higher rate of death in the supplemented group. On-
going trials are evaluating the role that vitamin D may
play on survival in patients with metastatic breast can-
cer, chronic lymphoid leukaemia and melanoma [26].
Moreover, further research is required for other out-
comes. For example, initial results show a possible role
vitamin D supplementation may play in reducing aroma-
tase inhibitor-induced joint symptoms [27] and loss of
bone density [20] in women with breast cancer.
Conclusion
In conclusion, in this population-based study in women
in the UK, our results do not support any association
between longer compared to short vitamin D supple-
mentation and beneficial survival from breast, colorectal,
Table 3 The association of vitamin D and calcium supplementation with survival from selected cancers in women: sensitivity
analysis
Deaths Cases Person- Basic model Adjusted model
Years HR 95 % CI HR 95 % CI
Breast cancer
3+ prescriptions 176 670 1890.8 1.05 0.79 to 1.40 1.08 0.81 to 1.44
1–2 prescriptions 60 223 685.3 1 1
Any 236 893 2576.0 0.81 0.71 to 0.92 0.80 0.70 to 0.91
None 1867 10,219 38976.0 1 1
Colorectal cancer
3+ prescriptions 148 332 708.2 1.08 0.76 to 1.54 1.06 0.74 to 1.52
1–2 prescriptions 45 111 247.8 1 1
Any 193 443 956.0 0.96 0.82 to 1.12 0.95 0.82 to 1.11
None 1533 3679 10338.3 1 1
Lung cancer
3+ prescriptions 251 324 283.8 1.22 0.95 to 1.56 1.22 0.94 to 1.57
1–2 prescriptions 87 109 119.3 1 1
Any 338 433 403.0 1.09 0.98 to 1.21 1.09 0.98 to 1.22
None 2418 2919 3069.1 1 1
Gynaecologic cancer
3+ prescriptions 78 163 372.6 1.27 0.76 to 2.12 1.24 0.71 to 2.18
1–2 prescriptions 21 61 145.6 1 1
Any 99 224 518.1 0.94 0.75 to 1.17 0.95 0.76 to 1.19
None 1052 2755 8205.8 1 1
This sensitivity analysis excludes all supplements prescribed in the year prior to cancer diagnosis
The basic model is adjusted for age and period; the adjusted model is further adjusted for smoking, alcohol, BMI and area-level deprivation
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lung, ovarian or uterine cancers. Women who had been
prescribed a vitamin D supplement exhibited better
survival. We suggest that previous observational data
may have been subject to confounding by indication.
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